Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Clinical trial NCT01649271 · COMPLETED
Trial details
- NCT number
- NCT01649271
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2012-07-23
- Primary completion
- 2016-06-23
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.